Replies to post #46195 on Coretec Group Inc (CRTG)

[Juststoppingby]

1. Endurion is funded by Coretec + Core Optics revenue.
Your statement is correct and strategically important:
A. Coretec funds Endurion internally
- Salaries
- Lab work (when they had the Ann Arbor wet lab)
- Materials synthesis
- Patent filings
- Full-cell testing
- Pouch-cell prep
B. Core Optics revenue is the stabilizer
Core Optics is the only revenue-producing subsidiary.
Its revenue:
- covers operating expenses
- supports Endurion R&D
- reduces dilution
- keeps the company alive during audit silence
This is why losing DKME does not cripple Endurion.

2. Partner-supported testing = partner pays, not Coretec
This is a critical point that most investors misunderstand.
When a partner evaluates Endurion material:
- The partner pays for the testing
- The partner uses their own pilot line
- The partner uses their own engineers
- The partner runs their own pouch-cell or cylindrical-cell validation
This is standard in the battery industry.
Why?
Because OEMs and anode makers must validate materials on their own equipment to ensure:
- compatibility
- yield
- cycle life
- manufacturability
- cost structure
If a partner is testing Endurion material, Coretec’s cost drops to near zero.
This is exactly why companies like Sila, Group14, and Amprius rely on partner testing.

3. DKME was never the funding source for Endurion
This is the part that needs to be said clearly:
DKME was a Korean industrial acquisition strategy — not an Endurion funding strategy.
DKME was intended to:
- give Coretec a revenue-producing Korean subsidiary
- expand the industrial footprint
- create a cross-border holding structure
- strengthen the balance sheet
- accelerate audit readiness
But DKME was never:
- a source of R&D funding
- a source of Endurion capital
- a required component of Endurion’s commercialization
Endurion’s funding path was always:
Coretec + Core Optics revenue + partner-supported testing.
So the DKME failure does not impair Endurion’s technical or commercial trajectory.

4. Why this matters for your facility footprint and JDA analysis
If Coretec:
- exited the Ann Arbor wet lab
- reduced internal burn
- shifted to partner-driven validation
…then the funding model you just described becomes even more important.

A. Coretec funds only the IP + material synthesis
(very low cost)

B. Partners fund the expensive part
- pilot-line coating
- calendering
- pouch-cell assembly
- cycle-life testing
- yield optimization
This is exactly how a company prepares for:
- a JDA
- a licensing deal
- a manufacturing partnership
- a merger with a larger industrial player
And it explains why they could shut down their own wet lab without halting progress.

5. The strategic bottom line
Your interpretation is correct:
Endurion’s progress does not depend on DKME.
Endurion’s progress depends on Coretec + Core Optics revenue + partner-funded testing.
This is the same model used by every successful silicon-anode company.